search
Back to results

Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic . (Cholangioscopy)

Primary Purpose

Cholangiocarcinoma, Biliary Stricture

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
single operator cholangioscopy
ERCP guided brushing and biopsy
Sponsored by
Asian Institute of Gastroenterology, India
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Cholangiocarcinoma focused on measuring ERCP, cholangioscopy

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age 18 or older.
  2. Willing and able to comply with the study procedures and provide written informed consent to participate in the study
  3. Biliary obstructive symptoms
  4. Indeterminate biliary stricture suspected to be intrinsic based on prior imaging

Exclusion Criteria:

  1. Contraindications for endoscopic techniques
  2. Prior ERCP for assessment of indeterminate biliary stricture
  3. Pancreatic head mass identified on prior non-invasive imaging and thought to be the cause of the biliary obstructive symptoms

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Active Comparator

    Arm Label

    Control arm - ERCP arm

    Study arm - cholangioscopy arm

    Arm Description

    Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed

    If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.

    Outcomes

    Primary Outcome Measures

    Diagnostic accuracy of cholangioscopy or cholangiography
    Malignancy will be determined by cytology or histology on tissue sampling during the index procedure, or from other tissue acquisition or surgical specimen histopathology up to 6 months after the index procedure.The assessed strictures will be considered benign if there was no confirmation of malignancy by 6 months after the index procedure. • Overall diagnostic accuracy will be assessed for ERCP impression of malignancy, ERCP-guided brushing and biopsies separately and combined, SpyDS impression of malignancy and SpyBite biopsies

    Secondary Outcome Measures

    Occurrence and severity of procedure related serious adverse events
    Occurrence and severity of procedure related serious adverse events from index procedure through 30 days after procedure.
    Technical success of procedure
    Technical success of procedure defined as ability to collect tissue deemed adequate for cytology or histology. Indeterminate or equivocal or atypical or non-conclusive cytology or histology will be considered failures to this endpoint
    Additional diagnostic accuracy metrics: Sensitivity, specificity, positive predictive value, negative predictive value.
    Additional diagnostic accuracy metrics: Sensitivity, specificity, positive predictive value, negative predictive value. The assessed strictures will be considered benign if there was no confirmation of malignancy by 6 months after the index procedure
    Impact of ERCP or cholangioscopy on patient management.
    Number of patients in whom management plan is altered based on ERCP or cholangioscopy will be determined
    Number of patients needed additional diagnostic procedures beyond the index procedure for final diagnosis
    Need for additional diagnostic procedures beyond the index procedure will be noted
    Number of accessories used
    The total number of accessories used during the procedure in both arms will be determined.
    Duration of procedure from duodenoscope in to duodenoscope out
    Duration of procedure is defined as time from duodenoscope in to duodenoscope out
    Correlation between impression of malignancy and cytopathology in the ERCP arm compared to the cholangioscopy arm
    Number of participants will be compared for outcome of visual impression ( benign/ malignant disease) on ERCP or cholangioscopy with final out come of cytopathology in both arms.

    Full Information

    First Posted
    April 25, 2017
    Last Updated
    May 4, 2017
    Sponsor
    Asian Institute of Gastroenterology, India
    Collaborators
    Prince of Wales Hospital, Shatin, Hong Kong, Evangelisches Krankenhaus Düsseldorf
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03140007
    Brief Title
    Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic .
    Acronym
    Cholangioscopy
    Official Title
    Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic - a Randomized Controlled Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2017
    Overall Recruitment Status
    Unknown status
    Study Start Date
    June 15, 2017 (Anticipated)
    Primary Completion Date
    February 15, 2018 (Anticipated)
    Study Completion Date
    June 15, 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Asian Institute of Gastroenterology, India
    Collaborators
    Prince of Wales Hospital, Shatin, Hong Kong, Evangelisches Krankenhaus Düsseldorf

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Primary Objective: To assess the diagnostic accuracy of cholangioscopy-based assessment using SpyDS technology compared to cholangiography-based assessment using ERCP-guided biopsy and brushing in patients with indeterminate biliary strictures in the setting of cholangiocarcinoma.
    Detailed Description
    Study Design : Prospective,multi-center, randomized controlled, Post market Study (PMS) Two groups: Control arm - ERCP arm: ERCP impression and ERCP-guided brushing and biopsy Study arm - Cholangioscopy arm: SpyDS impression and SpyDS-guided SpyBite biopsy Randomization 1:1 ratio. Primary Endpoint: Diagnostic accuracy of cholangioscopy or cholangiography assessed at 6 months after initial ERCP procedure Malignancy will be determined by cytology or histology on tissue sampling during the index procedure, or from other tissue acquisition or surgical specimen histopathology up to 6 months after the index procedure. Overall diagnostic accuracy. The assessed strictures will be considered benign if there was no confirmation of malignancy by 6 months after the index procedure. Overall diagnostic accuracy will be assessed for ERCP impression of malignancy ERCP-guided brushing and biopsies separately and combined* SpyDS impression of malignancy SpyBite biopsies In case of discordant results, the following will be followed for the combined pathology/cytology measure: If at least one is malignancy, then combine metric is malignant If both are benign or one is benign and one is non-diagnostic, then combined metric is benign If both are non-diagnostic, then combined metric is non-diagnostic Secondary Endpoints: Occurrence and severity of procedure related serious adverse events from index procedure through 30 days after procedure. Hospitalization and ICU admissions Technical success of procedure defined as ability to collect tissue deemed adequate for cytology or histology. Indeterminate or equivocal or atypical or non-conclusive cytology or histology will be considered failures to this endpoint. Correlation between impression of malignancy and cytopathology in the ERCP arm compared to the Cholangioscopy arm. Additional diagnostic accuracy metrics: Sensitivity, specificity, positive predictive value, negative predictive value. The assessed strictures will be considered benign if there was no confirmation of malignancy by 6 months after the index procedure. Impact of ERCP or cholangioscopy on patient management. Need for additional diagnostic procedures beyond the index procedure. Procedural measures: Type and number of devices used, Duration of procedure from duodenoscope in to duodenoscope out

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cholangiocarcinoma, Biliary Stricture
    Keywords
    ERCP, cholangioscopy

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Model Description
    prospective, multi-center, randomized controlled, post market study
    Masking
    Participant
    Masking Description
    prospective, multi-center, randomized controlled, post market study
    Allocation
    Randomized
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Control arm - ERCP arm
    Arm Type
    Other
    Arm Description
    Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
    Arm Title
    Study arm - cholangioscopy arm
    Arm Type
    Active Comparator
    Arm Description
    If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
    Intervention Type
    Device
    Intervention Name(s)
    single operator cholangioscopy
    Intervention Description
    If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
    Intervention Type
    Device
    Intervention Name(s)
    ERCP guided brushing and biopsy
    Intervention Description
    • If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
    Primary Outcome Measure Information:
    Title
    Diagnostic accuracy of cholangioscopy or cholangiography
    Description
    Malignancy will be determined by cytology or histology on tissue sampling during the index procedure, or from other tissue acquisition or surgical specimen histopathology up to 6 months after the index procedure.The assessed strictures will be considered benign if there was no confirmation of malignancy by 6 months after the index procedure. • Overall diagnostic accuracy will be assessed for ERCP impression of malignancy, ERCP-guided brushing and biopsies separately and combined, SpyDS impression of malignancy and SpyBite biopsies
    Time Frame
    6 Months
    Secondary Outcome Measure Information:
    Title
    Occurrence and severity of procedure related serious adverse events
    Description
    Occurrence and severity of procedure related serious adverse events from index procedure through 30 days after procedure.
    Time Frame
    30 days
    Title
    Technical success of procedure
    Description
    Technical success of procedure defined as ability to collect tissue deemed adequate for cytology or histology. Indeterminate or equivocal or atypical or non-conclusive cytology or histology will be considered failures to this endpoint
    Time Frame
    30 days
    Title
    Additional diagnostic accuracy metrics: Sensitivity, specificity, positive predictive value, negative predictive value.
    Description
    Additional diagnostic accuracy metrics: Sensitivity, specificity, positive predictive value, negative predictive value. The assessed strictures will be considered benign if there was no confirmation of malignancy by 6 months after the index procedure
    Time Frame
    6 months
    Title
    Impact of ERCP or cholangioscopy on patient management.
    Description
    Number of patients in whom management plan is altered based on ERCP or cholangioscopy will be determined
    Time Frame
    6 months
    Title
    Number of patients needed additional diagnostic procedures beyond the index procedure for final diagnosis
    Description
    Need for additional diagnostic procedures beyond the index procedure will be noted
    Time Frame
    6 months
    Title
    Number of accessories used
    Description
    The total number of accessories used during the procedure in both arms will be determined.
    Time Frame
    At index procedure.
    Title
    Duration of procedure from duodenoscope in to duodenoscope out
    Description
    Duration of procedure is defined as time from duodenoscope in to duodenoscope out
    Time Frame
    At index procedure
    Title
    Correlation between impression of malignancy and cytopathology in the ERCP arm compared to the cholangioscopy arm
    Description
    Number of participants will be compared for outcome of visual impression ( benign/ malignant disease) on ERCP or cholangioscopy with final out come of cytopathology in both arms.
    Time Frame
    6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Age 18 or older. Willing and able to comply with the study procedures and provide written informed consent to participate in the study Biliary obstructive symptoms Indeterminate biliary stricture suspected to be intrinsic based on prior imaging Exclusion Criteria: Contraindications for endoscopic techniques Prior ERCP for assessment of indeterminate biliary stricture Pancreatic head mass identified on prior non-invasive imaging and thought to be the cause of the biliary obstructive symptoms
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Mohan Ramchandani, MD DM
    Phone
    9701335444
    Email
    ramchandanimohan@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Mohan Ramchandani, MD DM
    Organizational Affiliation
    Asian Institute of Gastroenterology
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    31778656
    Citation
    Gerges C, Beyna T, Tang RSY, Bahin F, Lau JYW, van Geenen E, Neuhaus H, Nageshwar Reddy D, Ramchandani M. Digital single-operator peroral cholangioscopy-guided biopsy sampling versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized, multicenter trial (with video). Gastrointest Endosc. 2020 May;91(5):1105-1113. doi: 10.1016/j.gie.2019.11.025. Epub 2019 Nov 25.
    Results Reference
    derived

    Learn more about this trial

    Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic .

    We'll reach out to this number within 24 hrs